Literature DB >> 9188534

Large porous particles for pulmonary drug delivery.

D A Edwards1, J Hanes, G Caponetti, J Hrkach, A Ben-Jebria, M L Eskew, J Mintzes, D Deaver, N Lotan, R Langer.   

Abstract

A new type of inhalation aerosol, characterized by particles of small mass density and large size, permitted the highly efficient delivery of inhaled therapeutics into the systemic circulation. Particles with mass densities less than 0.4 gram per cubic centimeter and mean diameters exceeding 5 micrometers were inspired deep into the lungs and escaped the lungs' natural clearance mechanisms until the inhaled particles delivered their therapeutic payload. Inhalation of large porous insulin particles resulted in elevated systemic levels of insulin and suppressed systemic glucose levels for 96 hours, whereas small nonporous insulin particles had this effect for only 4 hours. High systemic bioavailability of testosterone was also achieved by inhalation delivery of porous particles with a mean diameter (20 micrometers) approximately 10 times that of conventional inhaled therapeutic particles.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9188534     DOI: 10.1126/science.276.5320.1868

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  177 in total

1.  Formulation and physical characterization of large porous particles for inhalation.

Authors:  R Vanbever; J D Mintzes; J Wang; J Nice; D Chen; R Batycky; R Langer; D A Edwards
Journal:  Pharm Res       Date:  1999-11       Impact factor: 4.200

2.  Bacterial inactivation by using near- and supercritical carbon dioxide.

Authors:  A K Dillow; F Dehghani; J S Hrkach; N R Foster; R Langer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

3.  Hollow porous particles in metered dose inhalers.

Authors:  L A Dellamary; T E Tarara; D J Smith; C H Woelk; A Adractas; M L Costello; H Gill; J G Weers
Journal:  Pharm Res       Date:  2000-02       Impact factor: 4.200

Review 4.  Sustained release drug delivery to the lungs: an option for the future.

Authors:  J G Hardy; T S Chadwick
Journal:  Clin Pharmacokinet       Date:  2000-07       Impact factor: 6.447

5.  Use of solid corrugated particles to enhance powder aerosol performance.

Authors:  N Y Chew; H K Chan
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

6.  In vivo lung deposition of hollow porous particles from a pressurized metered dose inhaler.

Authors:  Peter H Hirst; Gary R Pitcairn; Jeff G Weers; Thomas E Tarara; Andrew R Clark; Luis A Dellamary; Gail Hall; Jolene Shorr; Stephen P Newman
Journal:  Pharm Res       Date:  2002-03       Impact factor: 4.200

Review 7.  Fundamental effects of particle morphology on lung delivery: predictions of Stokes' law and the particular relevance to dry powder inhaler formulation and development.

Authors:  Timothy M Crowder; Jacky A Rosati; Jeffry D Schroeter; Anthony J Hickey; Ted B Martonen
Journal:  Pharm Res       Date:  2002-03       Impact factor: 4.200

8.  Protein inhalation powders: spray drying vs spray freeze drying.

Authors:  Y F Maa; P A Nguyen; T Sweeney; S J Shire; C C Hsu
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

9.  Large porous particles for sustained protection from carbachol-induced bronchoconstriction in guinea pigs.

Authors:  A Ben-Jebria; D Chen; M L Eskew; R Vanbever; R Langer; D A Edwards
Journal:  Pharm Res       Date:  1999-04       Impact factor: 4.200

10.  Repurposing rosiglitazone, a PPAR-γ agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH.

Authors:  Jahidur Rashid; Ahmad Alobaida; Taslim A Al-Hilal; Samia Hammouda; Ivan F McMurtry; Eva Nozik-Grayck; Kurt R Stenmark; Fakhrul Ahsan
Journal:  J Control Release       Date:  2018-04-30       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.